Dr. Eugene K. Lee, M.D.
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- University of Missouri, Kansas City, School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 380
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Missouri, Kansas City, School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
KS license 04-36419 · MO license 2013015498
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Kansas Hospital Kansas City, KS
- University of Kansas Health System Olathe Hospital Olathe, KS
- Mosaic Life Care at St Joseph Saint Joseph, MO
- Cameron Regional Medical Center Cameron, MO
- Harrison County Community Hospital Bethany, MO
Medical groups
- Kansas University Physicians Inc (1,849 clinicians)
- Cameron Regional Medical Center Inc (63 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 380
- Services billed
- 932
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 199 | 172 |
| Diagnostic exam of bladder and urethra using an endoscope | 139 | 77 |
| Established patient office or other outpatient visit, 30-39 minutes | 81 | 73 |
| New patient office or other outpatient visit, 60-74 minutes | 49 | 49 |
| New patient office or other outpatient visit, 30-44 minutes | 20 | 20 |
| New patient office or other outpatient visit, 45-59 minutes | 20 | 20 |
| Established patient office or other outpatient visit, 40-54 minutes | 17 | 16 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 15 | 14 |
| Insertion of stent in ureter using an endoscope | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Kansas City, KS | 163 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Kansas City, KS | 97 |
| Finasteride Other prescribers in Kansas City, KS | 59 |
| Myrbetriq (mirabegron) Other prescribers in Kansas City, KS | 55 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Kansas City, KS | 30 |
| Cephalexin Other prescribers in Kansas City, KS | 19 |
| Nitrofurantoin Mono-Macro (nitrofurantoin monohyd/m-cryst) Other prescribers in Kansas City, KS | 12 |
| Ciprofloxacin Hcl Other prescribers in Kansas City, KS | 11 |
| Dutasteride Other prescribers in Kansas City, KS | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 8 payments worth $427 in total to this clinician.
| Histosonics, Inc. | $232 |
|---|---|
| Urogen Pharma, Inc. | $54.41 |
| Dendreon Pharmaceuticals LLC | $47.36 |
| Boston Scientific Corporation | $35.65 |
| Endo USA, Inc. | $24.71 |
| Calyxo, Inc. | $17.79 |
| Janssen Biotech, Inc. | $14.62 |
| Food and Beverage | $427 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $528,443 in research payments for these studies, mostly to the institutions running them.
- A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
Pfizer Inc. - A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
Medivation LLC. - A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette Guerin BCG and Recurred With High Risk Non Muscle Invasive Bladder Cancer NM…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.